logo
Charter-Cox Merger Review And The Rule Of Law

Charter-Cox Merger Review And The Rule Of Law

Forbes5 hours ago
Charter Communications and Cox Communications, two broadband and cable providers, are seeking merger approval from the Department of Justice and Federal Communications Commission. Biden antitrust enforcers — which often relied on static market share snapshots to pursue antitrust claims, failing to consider broader market dynamics — might have sued to block this deal, only to be later overruled by the courts, which was a common occurrence during the Biden Administration. However, with the Trump administration restoring traditional antitrust norms grounded in law, precedent, and full-market analysis, the Charter-Cox deal should have a clear path forward.
Why Specifics Matter
Charter and Cox operate broadband services in largely distinct territories. Charter serves 41 states, focusing mainly on suburban and urban markets, while Cox's footprint is largely concentrated in areas that Charter hardly services, such as Arizona, Kansas, Oklahoma, and the City of Las Vegas. This geographic separation indicates the merger will not eliminate direct competition.
Moreover, today, broadband competition extends well beyond cable providers. Fixed wireless, fiber entrants, and 5G networks have significantly diversified consumer choice. As for cable, an outsized number of American families have ceased paying for it. There were 68.7 million cable TV subscribers in 2024, compared to 98.7 million in 2016.
Add it all up, and it becomes clear that the scale created by this merger will strengthen the combined company's ability to innovate and compete against streaming platforms and wireless alternatives rapidly reshaping the market.
Modern Economically-Based Case Analysis Supports Approval
Prior to the mid-1970s, the U.S. Supreme Court routinely upheld federal government merger challenges, viewing virtually any merger as anticompetitive, without regard to close factual or economic analysis.
In General Dynamics(1974), however, a merger between two competing coal companies, the High Court applied a more nuanced approach. It recognized that the acquired firm did not have sufficient uncommitted coal reserves to be a significant future competitive force, and therefore its acquisition did not pose a substantial competitive threat.
Although the Supreme Court has not reviewed mergers since the mid-1970s (Congress repealed a law mandating direct appeals of mergers from lower courts to the Supreme Court), it has applied a fact-based, economically-sensitive approach in non-merger antitrust cases. Federal judges have taken this approach to heart in key merger analyses.
The district court in FTC v. Steris Corp. (2015) emphasized that speculation about potential future competition does not suffice to block a deal without concrete evidence. Charter and Cox are not current competitors in overlapping markets, and no credible evidence suggests this merger will harm consumer choice or raise prices.
Efficiency claims also should matter as Supreme Court Justice (then appeals court judge) Brett Kavanagh stressed in FTC v. Whole Foods Market and United States v. Anthem. The Charter-Cox deal is fully consistent with this principle because it is projected to provide $500 million in annual savings, which will enable substantial investment in rural broadband and next-generation network upgrades.
Though he did not author merger cases as an appeals court judge, in his other antitrust opinions Supreme Court Justice (and former antitrust professor) Neil Gorsuch showed dedication to the 'underlying economic efficiency rationale that undergirds modern mainstream antitrust analysis.'
Furthermore, the merger should pass muster under Brown Shoe, the Supreme Court's multifactor test for assessing whether a transaction may substantially lessen competition. Although its factors are characterized as 'overinclusive, underinclusive, or irrelevant' by the leading antitrust treatise writer, Professor Herbert Hovenkamp, Brown Shoe is still referenced in current federal merger guidelines and thus cannot be ignored.
The Brown Shoe factors center around eliminating existing rivalry, raising entry barriers, and accelerating harmful concentration. None of these are present in Charter-Cox, given the companies' minimal overlap, the influx of new broadband competitors, and the absence of any evidence that consumer choice or pricing would be harmed.
Past approvals of transactions such as AT&T/DirecTV and Comcast/NBCUniversal underscore that agencies have recognized the benefits of increased scale when paired with clear consumer advantages. Those deals involved greater overlap and more complex competition issues than Charter-Cox, and yet they were approved, albeit with conditions to preserve competition. This deal presents none of those overlap concerns while offering tangible public-interest benefits, including accelerated broadband expansion and improved service quality.
Statutes Mean What They Say — and They Matter Here
The Clayton Act only allows the DOJ and FTC to challenge mergers when there is evidence that they may substantially lessen competition, which does not appear to be the case here.
Further, Congress has empowered agencies to review mergers, but those powers are not unchecked.
The Communications Act asks that the FCC approve license transfers if they serve the 'public interest, convenience, and necessity.' The Charter-Cox merger includes commitments to expand fiber infrastructure and improve broadband access, especially in underserved rural areas, directly advancing the FCC's statutory mandate to promote widespread, reliable, high-speed internet service.
Judicial and Congressional Checks on Agency Overreach
Courts require agencies to provide reasoned, evidence-supported analyses, and they don't hesitate to override agency decisions when necessary.
Congress also plays a vital oversight role over federal enforcement through the House and Senate Judiciary and Commerce Committees. This legislative check preserves the constitutional separation of powers and guards against regulatory overreach.
Conclusion
Agencies respecting statutory boundaries and basing their decisions on economic evidence is important, because it is how companies and consumers gain the predictability needed to plan investments that drive innovation and infrastructure. On the other hand, when agencies ignore these limits, the merger approval process turns into a politicized one, where power is shifted from markets to government negotiators.
When federal merger enforcement decisions become unpredictable, the rule of law erodes, and regulatory uncertainty deepens.
The Trump administration thus far has indicated that it seeks to enhance predictability by reinstituting a commonsense fact-based economically-centered merger review policy. Here's hoping that it will demonstrate its commitment to such an approach by fully assessing the hard facts and recognizing the factors that support the Charter-Cox deal.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi
Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi

Yahoo

time24 minutes ago

  • Yahoo

Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi

We recently published . Hudbay Minerals Inc. (NYSE:HBM) is one of the best-performing stocks on Wednesday. Hudbay Minerals grew its share prices for a second day on Wednesday, up 15.03 percent to close at $11.33 apiece, following an impressive earnings performance and a $600-million investment from Mitsubishi Corp. In its updated report, Hudbay Minerals Inc. (NYSE:HBM) said it swung to a net income attributable to shareholders of $117.7 million from an attributable net loss of $16.5 million in the same period last year, driven by higher gross margins and strong cost control. Revenues increased by 26 percent to $536.4 million from $425.5 million year-on-year. 'With the strong performance in the first half of the year, we are reaffirming our full year consolidated production guidance and are favourably tracking well below our full year consolidated cost guidance for 2025,' said Hudbay Minerals Inc. (NYSE:HBM) President and CEO Peter Kukielski. For the full-year period, the company is targeting to produce between 117,000 and 149,000 tons of copper, as well as 247,500 to 308,000 ounces of gold. In other news, Hudbay Minerals Inc. (NYSE:HBM) was able to raise $600 million in fresh funds from Mitsubishi Corp. after the latter acquired a 30-percent stake in Copper World LLC. Under the agreement, Mitsubishi will pay an upfront cash of $420 million, with the balance to serve as a matching contribution within an 18-month period. While we acknowledge the potential of HBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

Yahoo

time24 minutes ago

  • Yahoo

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

Yahoo

time24 minutes ago

  • Yahoo

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store